First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).Karen A. Autio,Celestia S. Higano, Luke T. Nordquist,Leonard Joseph Appleman,Tian Zhang,Xinhua Zhu,Hani M. Babiker,Nicholas J. Vogelzang,Sandip Prasad,Michael Thomas Schweizer,Stephane Billotte,Joseph Binder,Nora Cavazos,Ruifeng Li,Kam Chan,Helen Cho,Michael Dermyer,Robert Hollingsworth,Kenneth Alan Kern,Daniel P. PetrylakJOURNAL OF CLINICAL ONCOLOGY（2021）引用 1|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
